Physician profile
Ed Haggag
NPI 1033138383
$8,877.91
in general payments reported to CMS, 2019-2025
31 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $73.19 · 2021: $976 · 2022: $1,902 · 2023: $1,823 · 2024: $2,262 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,716.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,845.18 | 2021-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $1,331.27 | 2021-2025 | Xtampza |
| Scilex Pharmaceuticals INC. | $1,238.23 | 2019-2025 | Ztlido |
| Abbvie INC. | $1,138.63 | 2021-2025 | |
| Pfizer INC. | $584.16 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $406.17 | 2023-2025 | Quviviq, Quviviq |
| Tersera Therapeutics LLC | $350.21 | 2021-2025 | Prialt |
| Ibsa Pharma INC. | $320.29 | 2021-2024 | Tirosint, Licart, Tirosint |
| Redhill Biopharma INC. | $230.74 | 2021-2022 | |
| Valinor Pharma, LLC | $185.11 | 2025 | Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $171.24 | 2021-2025 | Trintellix |
| Amgen INC. | $119.93 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $119.37 | 2022 | |
| Uswm, LLC | $111.19 | 2021 | |
| Biodelivery Sciences International, INC. | $96.47 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $93.39 | 2021 | |
| Arbor Pharmaceuticals, INC. | $88.41 | 2021 | |
| Azurity Pharmaceuticals, INC. | $62.33 | 2024 | Horizant |
| Axsome Therapeutics, INC. | $58.77 | 2025 | Symbravo |
| Almatica Pharma LLC | $46.46 | 2023 | Gralise |
| Grt US Holding, INC. | $44.34 | 2021 | |
| Si-Bone, INC. | $40.02 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $29.60 | 2023 | Kristalose |
| Vertex Pharmaceuticals Incorporated | $26.40 | 2025 | |
| Tonix Medicines, INC. | $26.24 | 2025 | Tonmya |
| Bioventus LLC | $22.14 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.28 | 2021 | |
| Medtronic, INC. | $21.26 | 2024 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.53 | 2022 | |
| Horizon Therapeutics Plc | $16.39 | 2021 | |
| Orexo US, INC. | $14.16 | 2025 | Zubsolv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ed Haggag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.